Stock Watch: Pfizer’s Q2 Windows Into Wider 2024 Issues
Vaccine Sales And China Continue As Second-Quarter Headwinds
One company’s weak quarterly sales should not make a pharmaceutical winter. But combine the lower sales of major vaccine families across three companies’ portfolios with weak demand in China and it starts to feel chilly.
